Cited 2 times in
Glycated Albumin and Glycated Albumin/HbA1c Predict the Progression of Coronavirus Disease 2019 from Mild to Severe Disease in Korean Patients with Type 2 Diabetes
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 안철우 | - |
dc.date.accessioned | 2022-05-09T17:23:11Z | - |
dc.date.available | 2022-05-09T17:23:11Z | - |
dc.date.issued | 2022-04 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/188538 | - |
dc.description.abstract | Hyperglycemia is among the main risk factors for severe COVID-19. We evaluated the association of glycated albumin (GA) and GA/HbA1c ratio with progression of COVID-19 from mild to severe disease in patients with type 2 diabetes mellitus (T2DM). Our retrospective study included 129 patients aged over 18 years with COVID-19 and T2DM who did not have any need of oxygen supplement. Of these, 59 patients whose COVID-19 was aggravated and required oxygen supplementation eventually were classified as having severe disease. Clinical and laboratory data were compared between mild and severe cases. The median of GA (18.4% vs. 20.95%, p = 0.0013) and GA/HbA1c (2.55 vs. 2.68, p = 0.0145) were higher in severe disease than in mild disease and positively correlated with C-reactive protein (Kendal Tau coefficient 0.200 and 0.126, respectively; all p < 0.05). Multiple logistic regression analysis showed that GA (odds ratio (OR), 1.151; 95% confidence interval (CI), 1.024–1.294) and GA/HbA1c (OR, 8.330; 95% CI, 1.786–38.842) increased the risk of severe disease. Patients with GA 20% or higher were 4.03 times more likely to progress from mild to severe disease. GA and GA/HbA1c ratio predicted progression of COVID-19 from mild to severe disease in patients with T2DM. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | MDPI AG | - |
dc.relation.isPartOf | JOURNAL OF CLINICAL MEDICINE | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | Glycated Albumin and Glycated Albumin/HbA1c Predict the Progression of Coronavirus Disease 2019 from Mild to Severe Disease in Korean Patients with Type 2 Diabetes | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Jeongseon Yoo | - |
dc.contributor.googleauthor | Youngah Choi | - |
dc.contributor.googleauthor | Shin Ae Park | - |
dc.contributor.googleauthor | Ji Yeon Seo | - |
dc.contributor.googleauthor | Chul Woo Ahn | - |
dc.contributor.googleauthor | Jaehyun Han | - |
dc.identifier.doi | 10.3390/jcm11092327 | - |
dc.contributor.localId | A02270 | - |
dc.relation.journalcode | J03556 | - |
dc.identifier.eissn | 2077-0383 | - |
dc.subject.keyword | COVID-19 | - |
dc.subject.keyword | SARS-CoV-2 | - |
dc.subject.keyword | type 2 diabetes mellitus | - |
dc.subject.keyword | glycated hemoglobin a | - |
dc.subject.keyword | glycated albumin to glycated hemoglobin ratio | - |
dc.subject.keyword | glycosylated serum albumin | - |
dc.subject.keyword | South Korea | - |
dc.contributor.alternativeName | Ahn, Chul Woo | - |
dc.contributor.affiliatedAuthor | 안철우 | - |
dc.citation.volume | 11 | - |
dc.citation.number | 9 | - |
dc.citation.startPage | 2327 | - |
dc.identifier.bibliographicCitation | JOURNAL OF CLINICAL MEDICINE, Vol.11(9) : 2327, 2022-04 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.